SCHEMBL3013083

SCHEMBL3013083

Cc1cccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(OC(F)(F)F)cc4)CC3)n2)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.40
RAB9A P51151 4/20 0.40
NPC1 O15118 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
RAF1 P04049 1/20 0.38
BRAF P15056 1/20 0.38
MAPT P10636 2/20 0.38
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38
LIPE Q05469 1/20 0.38
KIT P10721 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008527 0.93 SMN1; SMN2 (0.42) ARRAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3018152 0.90 RAB9A (0.43) RAB9ANPC1L3MBTL1SMN1; SMN2MAPT
SCHEMBL3016391 0.89 MAPT (0.48) ARRAB9ANPC1SMN1; SMN2MAPT
SCHEMBL3009438 0.87 SMN1; SMN2 (0.47) ARRAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3009239 0.87 SMN1; SMN2 (0.45) ARRAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3008321 0.86 AR (0.45) ARRAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3007567 0.86 AR (0.52) ARRAB9ANPC1SMN1; SMN2RAF1
SCHEMBL2999465 0.86 MAPT (0.53) ARL3MBTL1SMN1; SMN2MAPTUSP2
SCHEMBL3017109 0.85 AR (0.40) ARRAB9ANPC1L3MBTL1SMN1; SMN2
SCHEMBL3016320 0.85 MAPT (0.42) ARRAB9ANPC1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.